<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475407</url>
  </required_header>
  <id_info>
    <org_study_id>CRBF004</org_study_id>
    <nct_id>NCT03475407</nct_id>
  </id_info>
  <brief_title>The Effects of Intravitreal Ozurdex Implant in DME</brief_title>
  <official_title>The Effects of Intravitral Ozurdex Implant in DME: Cytokine Change in Aqueous Humor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nune Eye Hospital, Seoul, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nune Eye Hospital, Seoul, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravitreal Ozurdex implant therapy improves visual outcome and OCT findings. The purpose of
      this study is that these results are correlated with the change of cytokine level known to be
      increased in DME patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Central foveal thickness(CFT, height in micrometers)</measure>
    <time_frame>Baseline, 1 week, 6 weeks, 12 weeks, 18 weeks, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of aqueous humor cytokine (VFGF, IL-2, IL-6,IL-8, MCP-1)</measure>
    <time_frame>Baseline, 6 weeks, 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Best corrected Visual acuity(BCVA, ETDRS scale)</measure>
    <time_frame>Baseline, 1 week, 6 weeks, 12 weeks, 18 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ozurdex intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex intravitreal injection</intervention_name>
    <description>Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline
AC paracentesis at 6 wk
intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patients of Type 1 or Type 2 Diabetes Mellitus fulfilling the following inclusion
        criteria shall be enrolled in the study:

          -  Patients of Non Proliferative Diabetic Retinopathy(NPDR) with clinically significant
             macular edema(CSME)

          -  Patients with Proliferative Diabetic Retinopathy(PDR) with CSME where proliferative
             component has been adequately treated with laser photocoagulation

          -  Diabetic patients with cystoids macular edema

          -  Minimum central thickness on OCT not less than 300 microns

          -  BCVA 20/30~20/320

        Exclusion Criteria:

          -  Patients with history of Anti-VEGF or steroid injection, any type of laser treatments,
             vitrectomy, cataract surgery within 6 months

          -  Patients with history of ocular hypertension or glaucoma

          -  Patients with media haze or pupillary non-dilation that does not allow good fundus
             photography, FFA and OCT

          -  Patients with macular ischemia on FFA

          -  Patients with active or suspected ocular or periocular infections including most viral
             diseases of the cornea and conjunctiva

          -  Patients whose posterior lens capsule is not intact.

          -  patients with known hypersensitivity to any components of this product.

          -  patients with vitreous hemorrhage

          -  patients who have systemic treatment effect on study results

          -  patients who enrolled other clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oh Woong Kwon, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nune Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oh Woong Kwon, MD, Ph D</last_name>
    <phone>+82+2+2086+7752</phone>
    <email>owkwon0301@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nune Eye Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-280</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Hae Lee, MD</last_name>
      <phone>+82-10-2765-5303</phone>
      <email>seastar01@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Oh Woong Kwon, MD, Ph D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Hae Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nune Eye Hospital, Seoul, Korea</investigator_affiliation>
    <investigator_full_name>Oh Woong Kwon</investigator_full_name>
    <investigator_title>Chief of retina center in Nune Eye Hospital</investigator_title>
  </responsible_party>
  <keyword>Diabetic macular edema</keyword>
  <keyword>cytokine</keyword>
  <keyword>dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

